5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer

E. Bolli, S. Saccomanno, G. Mondini, C. Aschele, A. Guglielmi, B. Ligas, M. Connio, A. Mori, R. Rosso, A. Sobrero, L. Tixi, V. Pugliese

Research output: Contribution to journalArticle

Abstract

A total of 20 patients with advanced pancreatic adenocarcinoma were enrolled in a phase II trial testing the activity of 5-fluorouracil given at 370 mg/m2 as a rapid i. v. bolus for 5 consecutive days, preceded by a rapid i. v. bolus of 200 mg/m2 5-methyltetrahydrofolic acid. The treatment was repeated every 4 weeks. The median age of the patients was 68 years and their median Eastern Cooperative Oncology Group (ECOG) performance status was 1. There were 7 patients with locally advanced disease and 13 with distant metastases (median, 2 sites). A median of 3 monthly cycles of treatment (range, 1-7) were given, with a corresponding dose intensity of 396 mg/m2 per week (86% of that planned). No complete response, 1 partial response, and 8 cases of disease stabilization were obtained. In general the regimen was well tolerated, with only 2 patients suffering from grade 3 stomatitis or diarrhea; the most common toxicity was nausea, which was experienced by almost 50% of the patients. The combination of 5-methyltetrahydrofolate plus 5-fluorouracil appears as little effective in this disease as 5-fluorouracil plus 5-formyltetrahydrofolate (leucovorin). It is suggested that bolus 5-fluorouracil is so inactive as an "effector agent" against pancreatic cancer that its biochemical modulation with exogenous high-dose reduced folates cannot improve the therapeutic outcome produced by the fluoropyrimidine in these patients.

Original languageEnglish
Pages (from-to)339-342
Number of pages4
JournalCancer Chemotherapy and Pharmacology
Volume35
Issue number4
DOIs
Publication statusPublished - Jul 1995

Keywords

  • 5-Fluorouracil
  • Pancreatic cancer
  • Reduced folates

ASJC Scopus subject areas

  • Pharmacology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of '5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer'. Together they form a unique fingerprint.

  • Cite this

    Bolli, E., Saccomanno, S., Mondini, G., Aschele, C., Guglielmi, A., Ligas, B., Connio, M., Mori, A., Rosso, R., Sobrero, A., Tixi, L., & Pugliese, V. (1995). 5-Fluorouracil plus 5-methyltetrahydrofolate in advanced pancreatic cancer. Cancer Chemotherapy and Pharmacology, 35(4), 339-342. https://doi.org/10.1007/BF00689455